ESSEXBIO-TECH：INTERIMREPORT2024.pdf

1、2024中期報告中期報告INTERIM REPORT 2024INTERIM REPORT2024ESSEX BIO-TECHNOLOGY LIMITEDiiPIONEERINGGLOBALREGENERATIVESCIENCE&TECHNOLOGYESSEX BIO-TECHNOLOGY LIMITEDiiTOMORROWS TODAYContents2Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income3Condensed Consolidated Statement of Fin

2、ancial Position4Condensed Consolidated Statement of Changes in Equity5Condensed Consolidated Statement of Cash Flows7Notes to the Interim Condensed Consolidated Financial Statements23Management Discussion and Analysis34Additional Information38Corporate Information2ESSEX BIO-TECHNOLOGY LIMITEDThe boa

3、rd(the“Board”)of directors(the“Directors”)of Essex Bio-Technology Limited(the“Company”)presents the unaudited interim condensed consolidated financial statements of the Company and its subsidiaries(collectively,the“Group”)for the six months ended 30 June 2024 together with the comparative figures fo

4、r the corresponding period in 2023 and the relevant explanatory notes as set out below.CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOMEFor thesix monthsended 30 June20242023(Unaudited)(Unaudited)NotesHK$000HK$000 Turnover4&5811,630899,359Cost of sales(87,018)(88,897)

5、Gross profit724,612810,462Other revenue,and other gains and losses631,34426,348Distribution and selling expenses(450,305)(520,663)Administrative expenses(102,879)(101,277)Finance costs7(3,442)(9,436)Share of loss of an associate(1,950)(579)Profit before income tax8197,380204,855Income tax9(39,940)(3

6、5,044)Profit for the period157,440169,811 Other comprehensive incomeItems that may be reclassified subsequently to profit or loss:Exchange differences on translation of financial statements of foreign operations(41,016)(79,627)Items that will not be reclassified subsequently to profit or loss:Change